Deliver Your News to the World

SmallCapNewsRelease: (OTC: NFRM) To Be Exclusive Partner With Globe Laboratories


WEBWIRE

JERICHO, NY—(SmallCapNewsRelease)—March 3rd, 2011, National Pharmaceuticals Corp. (OTC: NFRM) announced today they have reached an agreement in principal with Globe Laboratories to become National’s exclusive partner to develop its drugs to the final stage of development.

National is focused on leading edge technologies for the treatment of human diseases. National Pharmaceuticals licenses mid stage development drugs for further development and future global marketing. The company hopes to negotiate the final terms of “GLB333” in the near future.

To view the entire press release, please visit http://finance.yahoo.com/news/National-Pharmaceuticals-Corp-iw-4064987853.html?x=0&.v=1

SmallCapNewsRelease gainers are Global Defense Technology (NASDAQ: GTEC) America Service Group (NASDAQ: ASGR) Acclr8 Technology Corp (AMEX: AXK) DUSA Pharmaceuticals (NASDAQ: DUSA) Superconductor Technologies (NASDAQ: SCON) LiveDeal Inc (NASDAQ: LIVE) Sauer-Danfoss Inc (NYSE: SHS) Clean Diesel Technologies (NASDAQ: CDTI)

SmallCapNewsRelease decliners are Amylin Pharmaceuticals (NASDAQ: AMLN) The Connecticut Bank and Trust (NASDAQ: CTBC) Valley National Bancorp (NASDAQ: VLYWW) Zion Oil & Gas (NASDAQ: ZNWAZ) Sigma Designs (NASDAQ: SIGM) Alkermes (NASDAQ: ALKS) China Botanic Pharmaceuticals (AMEX: CBP) Waccamaw Bankshares (NASDAQ: WBNK)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Small Cap News Release twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation, do no trading of any kind and send no faxes or emails.



WebWireID133210




 
 Pharmaceuticals
 Penny Stock
 Investment
 Yahoo
 Small Cap News


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.